Adamis Pharmaceuticals Corporation (ADMP)

Business: Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease in the United States.

IPO Date: 14-Aug-1995

Co-Founder, CEO, Pres & Director: Mr. David J. Marguglio

Chief Medical Officer: Dr. Ronald B. Moss M.D.

Listing: NASDAQ: ADMP

Country: United States

Headquarters: San Diego, CA

Website: https://www.adamispharmaceuticals.com

Market cap: $56.09 Mln

Revenue (TTM): $8.02 Mln

Earnings (TTM): $-37.76 Mln

Cash: $17.77 Mln

Total Debt: $2.46 Mln

Insider's Holding: 1.07%

Liquidity: Low

52 Week range: $0.31 - 1.48

Shares outstanding: 149,983,008

10 Years Aggregate:

• CFO: $-169.39 Mln
• EBITDA: $-222.71 Mln
• Net Profit: $-245.79 Mln